Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
POEMS syndrome complicated by follicular lymphoma.
SASAKI T, OHNISHI S, ONISHI R, TAKEMURA R, KOBAYASHI Y, SUZUKI M, DAZAI M, HATA T, YAMAMOTO J, ODA H, TAKAHASHI T, OGASAWARA K, MIYAGISHIMA T. SASAKI T, et al. Among authors: dazai m. Rinsho Ketsueki. 2009 Nov;50(11):1621-5. Rinsho Ketsueki. 2009. PMID: 20009437
Study protocol of HGCSG1404 SNOW study: a phase I/II trial of combined chemotherapy of S-1, nab-paclitaxel and oxaliplatin administered biweekly to patients with advanced gastric cancer.
Kawamoto Y, Komatsu Y, Yuki S, Sawada K, Muranaka T, Harada K, Nakatsumi H, Fukushima H, Ishiguro A, Dazai M, Hatanaka K, Nakamura M, Iwanaga I, Uebayashi M, Sogabe S, Kobayashi Y, Miyagishima T, Ono K, Sakamoto N, Sakata Y. Kawamoto Y, et al. Among authors: dazai m. BMC Cancer. 2017 Dec 8;17(1):837. doi: 10.1186/s12885-017-3850-z. BMC Cancer. 2017. PMID: 29221445 Free PMC article. Clinical Trial.
Study protocol of the HGCSG1803: a phase II multicentre, non-randomised, single-arm, prospective trial of combination chemotherapy with oxaliplatin, irinotecan and S-1 (OX-IRIS) as first-line treatment for metastatic or relapsed pancreatic cancer.
Nakano S, Kawamoto Y, Yuki S, Harada K, Miyagishima T, Sogabe S, Dazai M, Sato A, Ishiguro A, Nakamura M, Kajiura S, Takahashi Y, Tateyama M, Hatanaka K, Tsuji Y, Sasaki T, Shindo Y, Kobayashi T, Yokota I, Sakamoto N, Sakata Y, Komatsu Y. Nakano S, et al. Among authors: dazai m. BMJ Open. 2022 May 9;12(5):e048833. doi: 10.1136/bmjopen-2021-048833. BMJ Open. 2022. PMID: 35534074 Free PMC article.
Study protocol for HGCSG1801: A multicenter, prospective, phase II trial of second-line FOLFIRI plus aflibercept in patients with metastatic colorectal cancer refractory to anti-EGFR antibodies.
Nakatsumi H, Komatsu Y, Muranaka T, Yuki S, Kawamoto Y, Harada K, Dazai M, Tateyama M, Sasaki Y, Miyagishima T, Tsuji Y, Katagiri M, Nakamura M, Sogabe S, Hatanaka K, Meguro T, Kobayashi T, Ishiguro A, Muto O, Shindo Y, Kotaka M, Ando T, Takagi R, Sakamoto N, Sakata Y. Nakatsumi H, et al. Among authors: dazai m. Front Oncol. 2022 Nov 9;12:939425. doi: 10.3389/fonc.2022.939425. eCollection 2022. Front Oncol. 2022. PMID: 36439491 Free PMC article.
Correlation of UGT1A1 Gene Polymorphisms or Prior Irinotecan Treatment and Treatment Outcomes of Nanoliposomal-Irinotecan plus 5-Fluorouracil/Leucovorin for Pancreatic Ductal Adenocarcinoma: A Multicenter, Retrospective Cohort Study (HGCSG2101).
Harada K, Yamamura T, Muto O, Nakamura M, Sogabe S, Sawada K, Nakano S, Yagisawa M, Muranaka T, Dazai M, Tateyama M, Kobayashi Y, Kato S, Hatanaka K, Kawamoto Y, Yuki S, Sakata Y, Sakamoto N, Komatsu Y. Harada K, et al. Among authors: dazai m. J Clin Med. 2023 Feb 17;12(4):1596. doi: 10.3390/jcm12041596. J Clin Med. 2023. PMID: 36836140 Free PMC article.
Impact of single-heterozygous UGT1A1 on the clinical outcomes of irinotecan monotherapy after fluoropyrimidine and platinum-based combination therapy for gastric cancer: a multicenter retrospective study.
Nakano S, Yuki S, Kawamoto Y, Nakatsumi H, Ando T, Kajiura S, Yoshikawa A, Harada K, Hatanaka K, Tanimoto A, Ishiguro A, Honda T, Dazai M, Sasaki T, Sakamoto N, Komatsu Y. Nakano S, et al. Among authors: dazai m. Int J Clin Oncol. 2020 Oct;25(10):1800-1806. doi: 10.1007/s10147-020-01720-y. Epub 2020 Jul 14. Int J Clin Oncol. 2020. PMID: 32666389 Free PMC article.
Phase II Study of Ramucirumab Plus Irinotecan Combination Therapy as Second-Line Treatment in Patients with Advanced Gastric Cancer: HGCSG1603.
Kawamoto Y, Yuki S, Sawada K, Nakamura M, Muto O, Sogabe S, Shindo Y, Ishiguro A, Sato A, Tsuji Y, Dazai M, Okuda H, Meguro T, Harada K, Sekiguchi M, Okada K, Ito YM, Sakata Y, Sakamoto N, Komatsu Y. Kawamoto Y, et al. Among authors: dazai m. Oncologist. 2022 Aug 5;27(8):e642-e649. doi: 10.1093/oncolo/oyac086. Oncologist. 2022. PMID: 35579511 Free PMC article. Clinical Trial.
18 results